TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04762147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol, the group P
Description: The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
Study: NCT00369824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra TM
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra TM
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra TM
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM
Description: One dose of vaccine administered intramuscularly
Study: NCT00768950

Intervention type: PROCEDURE
Intervention: Capsule endoscopy examination
Description: Examination of the small bowel with endoscopic videocapsule

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Endoscopic examination of the large bowel and terminal ileum
Study: NCT03827265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
Study: NCT04762147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl, group-F administered as an active comparator
Description: The fentanyl 2mcg/kg was administered at the time induction of anaesthesia for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
Study: NCT01062594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Role of exercise
Description: Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise program
Description: Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
Study: NCT01287533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: monthly dosage of ibandronate 150mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: monthly dosage of placebo
Study: NCT00645567

Intervention type: DEVICE
Intervention: Unassisted Manual Transfer
Description: No device assistance

Intervention type: DEVICE
Intervention: Standard Transfer Board
Description: Flat surface board

Intervention type: DEVICE
Intervention: Glide n' Go
Description: Flip down power lift chair

Intervention type: DEVICE
Intervention: Easy Reach lift
Description: Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height

Intervention type: DEVICE
Intervention: Ryno lift
Description: Lift for the wheelchair
Study: NCT02583802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ear pills
Description: The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shengmai capsule
Description: The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
Study: NCT00125190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1 (mecasermin) for a period of 86 weeks
Description: Once a day rhIGF-1 injections
Study: NCT02140138

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CV9104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle free injection device (Tropis®)
Study: NCT01972009

Intervention type: PROCEDURE
Intervention: Cardiac catheterisation
Description: Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.

Intervention type: PROCEDURE
Intervention: Cardiac catheterisation
Description: Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
Study: NCT01344837

Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Immunohistochemistry Staining Method
Description: Correlative studies

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Correlative studies

Intervention type: GENETIC
Intervention: Microarray Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Study of Socioeconomic and Demographic Variables
Description: Correlative studies

Intervention type: GENETIC
Intervention: Western Blotting
Description: Correlative studies
Study: NCT02939937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
Study: NCT02953782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study: NCT03827265

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
Study: NCT02953782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously
Study: NCT04272801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen, letrozole, anastrozole, or exemestane
Description: choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reported outcomes
Description: Questionnaire inquiries include the following:~* how cancer affects daily living~* beliefs about medicines and sensitivity to medicine~* symptoms~* adherence to endocrine therapy~* general health and well being~* depression and anxiety~* preference regarding radiation therapy
Study: NCT02688049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffold/mesenchymal stem cells transplantation
Description: Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffold/neural stem cells transplantation
Description: Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
Study: NCT02953782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously
Study: NCT01889966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: oral Sildenafil 3 x 20 mg for 90 days
Study: NCT03994263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITind device implant
Description: device implanted for 5-7 days
Study: NCT03605719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02140138

Intervention type: DEVICE
Group type: OTHER
Intervention: needle free injection device (Tropis®)
Study: NCT00539292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary placement of a spring-loaded silo

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Closure
Description: primary closure of abdomen
Study: NCT02801071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15g L-citrulline daily p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02613806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmeditomidine
Description: Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
Study: NCT02234739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 2-week long intravenous instillation of voriconazole
Study: NCT05503212

Intervention type: OTHER
Intervention: Conservative treatment (CT)
Description: Best medical treatment without intravenous thrombolysis nor endovascular thrombectomy

Intervention type: OTHER
Intervention: Intravenous thrombolysis (IVT)
Description: Best medical treatment with intravenous thrombolysis but without endovascular thrombectomy

Intervention type: OTHER
Intervention: Endovascular thrombectomy (EVT) ± intravenous thrombolysis (IVT)
Description: Best medical treatment with endovascular thrombectomy with or without intravenous thrombolysis
Study: NCT01563237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIDI Arrow
Description: Implantation of MIDI Arrow
Study: NCT06614699

Intervention type: OTHER
Intervention: abdominal fat and muscle area
Description: Abdominal fat and muscle area were calculated based on abdominal CT.
Study: NCT02112656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox
Description: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dummy infusion
Description: Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
Study: NCT03162432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral Vitamin D3 therapy.
Study: NCT01235689

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
Study: NCT04614324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RhinAer ARC Stylus
Description: The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).
Study: NCT01778413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRIPLA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRIPLA
Study: NCT01994876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 1
Description: Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 1
Description: Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 2
Description: Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 2
Description: Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
Study: NCT01186276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: Dietary fiber supplements to be consumed daily for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch
Description: Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
Study: NCT00457626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Extemporaneous suspension of valsartan, orally.
Study: NCT01005290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pill
Description: A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
Study: NCT00946595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz/emtricitabin/tenofovir
Description: 1x600/200/245 mg per day (one tablet) between W0 et W98

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: 4 x 200/50 mg (4 tablets) once a day between W0 and W98
Study: NCT01235689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
Study: NCT00678093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of the SNAG technique
Description: SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
Study: NCT03026361

Intervention type: GENETIC
Intervention: global proteomic profiling
Description: Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.

Intervention type: GENETIC
Intervention: global proteomic profiling
Description: Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.

Intervention type: GENETIC
Intervention: global proteomic profiling
Description: Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.
Study: NCT03167905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural delivery system
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entonox
Description: Entonox will be given upon request in non-epidural group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Intramuscular pethidine (75mg/1.5ml) will be given upon request in non-epidural group.
Study: NCT03605719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Given IV